Webinar

Development of a multiplex assay for prediction of immunotherapy response in metastatic melanoma patients

Register here

May 18 2022

3:00 PM CEST

Online

Lunaphore webinar

Join Prof. Paolo Ascierto and Dr. Gabriele Madonna for an exclusive presentation during Melanoma Awareness Month.

May 18, 2022

Webinar

3:00 PM CEST

Online

Abstract:

Melanoma is the most aggressive among all skin cancers and is responsible for high mortality rate. Combined immunotherapies have demonstrated a greater efficacy to boost the immune system of melanoma patients. However, the clinical decision on which combination to be used and which patients will benefit the most from it, remains a challenge. Understanding the immune context of patients’ tumor and the identification of reliable biomarker redouts will assist clinicians in their decision. We developed a multiplex immunohistochemistry assay to profile the tumor microenvironment of metastatic melanoma patients who responded or not to combined immunotherapy. We used LabSat®, an automated stainer based on Lunaphore’s microfluidic technology, to analyze the expression of PD-L1, CD8 and LAG-3. Our results provide first-time evidence of a different expression pattern of these markers between responder and non-responder melanoma patients.

 

At the end of the webinar, there will be a live Q&A session, giving the opportunity to ask your questions to our speakers. Not available? Register anyway and access the webinar on-demand.

Speakers

Prof. Paolo Ascierto

Prof. Paolo Ascierto

Director of the Unit of Melanoma

National Tumor Institute G. Pascale, Naples, Italy

Dr. Ascierto is a member of the Steering Committee of Society of Melanoma Research (SMR) and the Board of Directors of Society of ImmunoTherapy of Cancer (SITC).

Dr. Gabriele Madonna

Dr. Gabriele Madonna

Health Researcher

National Tumor Institute G. Pascale, Naples, Italy

Related Events